Radioimmunotherapy study of ¹³¹I-labeled Atezolizumab in preclinical models of colorectal cancer.

ABSTRACT:

Background

Programmed cell death 1 ligand 1(PD-L1) is overexpressed in many tumors. The radionuclide-labeled anti-PD-L1 monoclonal antibody can be used for imaging and therapy of PD-L1 overexpressing cancer. Here, we described ¹³¹I-labeled Atezolizumab (¹³¹I-Atezolizumab, targeting PD-L1) as a therapeutic agent for colorectal cancer with PD-L1 overexpression.

Methods

¹³¹I-Atezolizumab was prepared by the Iodogen method. The expression levels of PD-L1 in different human colorectal cells were determined by flow cytometry, western blot and cell binding assay. The immunoreactivity of ¹³¹I-Atezolizumab to PD-L1 high-expressing cells was determined by immunoreactive fraction. The killing abilities of different concentrations of ^131<

SUBMITTER: Zhang L 

PROVIDER: S-EPMC9616992 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature